Tango Therapeutics, Inc.
Clinical trials sponsored by Tango Therapeutics, Inc., explained in plain language.
-
New pill targets Hard-to-Treat cancers with missing gene
Disease control Recruiting nowThis study is testing a new drug called TNG462 for people with advanced solid tumors that have a specific genetic deletion (MTAP). The drug is taken by mouth and aims to shrink or control tumor growth. The trial has two parts: first finding the best dose, then testing it in more …
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 01, 2026 11:28 UTC
-
New hope for Hard-to-Treat cancers: targeted combo trial opens
Disease control Recruiting nowThis study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene and, in some cases, has a RAS mutation. The goal is to find safe doses and see if the combinations shrink tumors. About 18…
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 01, 2026 11:26 UTC
-
New combo targets Hard-to-Treat cancers with STK11 mutation
Disease control Recruiting nowThis study tests an experimental drug called TNG260 combined with an immunotherapy (pembrolizumab) in people with advanced solid tumors that have a specific genetic change (STK11 mutation). The goal is to find the best dose and see if the combination is safe and can shrink tumors…
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC